Midostaurin
Myelodysplastic Syndrome With Excess Blasts-2
Stichting Hemato-Oncologie voor Volwassenen NederlandSmall moleculePhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the Myelodysplastic Syndrome With Excess Blasts-2 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Sumithira Vasu | Phase 2 | BB |
Gilteritinib Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 3 | BB |
Cytarabine Sumithira Vasu | Phase 2 | BB |
Cyclophosphamide Fred Hutchinson Cancer Center | Phase 2 | B |
Azacitidine Aptose Biosciences Inc. | Phase 2 | B |
View all 28 →
Same molecule, other indications
Midostaurin is also rated in:
acute myeloid leukemia, FLT3 internal tandem duplicationDormant
B
Indicative · Phase 3
61 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →